Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Up 10.1% - What's Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) traded up 10.1% on Wednesday . The company traded as high as $29.79 and last traded at $29.79. 300 shares were traded during mid-day trading, an increase of 210% from the average session volume of 97 shares. The stock had previously closed at $27.06.

Swedish Orphan Biovitrum Price Performance

The company has a market cap of $10.61 billion, a price-to-earnings ratio of 25.03 and a beta of 0.42. The company has a current ratio of 1.04, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31. The business has a fifty day moving average of $30.07 and a two-hundred day moving average of $29.33.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.06. The company had revenue of $649.61 million during the quarter, compared to analysts' expectations of $644.68 million. Swedish Orphan Biovitrum had a return on equity of 11.93% and a net margin of 16.05%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.